SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Daewon Pharmaceutical Reports Phase 3 Success for Padoprazan

Daewon Pharmaceutical said its next-generation stomach drug, padoprazan, succeeded in a Phase 3 clinical trial.

Related stories